Last year was one of the 'most eventful in US biosimilars history,' but these analysts say 2022 should be 'a turning point'
Though last year saw fewer market entrants in the biosimilar space than years past, Cardinal Health still called it one of the “most eventful” in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
